February 18, 2025 – A new chapter in cell & gene therapy begins today.

California, USA – EurekaBio, a leading upstream supplier in the CGT field, and VectorBuilder, a global expert in gene delivery technology, are proud to announce their synergistic strategic partnership. This alliance combines EurekaBio's revolutionary EuLV™ Stable Lentiviral Production System with VectorBuilder's GMP manufacturing and regulatory support expertise, aiming to accelerate the development of life-changing therapies worldwide.

Cooperation for Global Impact

With a proven track record of securing FDA IND approvals for their industrial partners, both companies bring complementary strengths:

• EurekaBio dominates viral vector scale-up production through its industry-first EuLV™ Stable Producer Stable Cell Line and automated CellSep® systems, delivering unprecedented consistency and cost efficiency.

• VectorBuilder powers research translation with its worldwide platform for creation of custom gene vectors, serving 4,500+ clients across 90+ countries – including top-tier pharmaceutical companies and 90% of the QS Top 100 universities and top-tier pharmaceutical companies.

Shaping the Future of CGT Manufacturing

Through this partnership, the two companies will deeply integrate the EuLV® system with VectorBuilder’s optimized virus packaging technology to provide clients with end-to-end solutions spanning process development, GMP production, and regulatory support. Previously, VectorBioVectorBuilder successfully validated the high-yield and high-quality attributes of the EuLV® system in large-scale reactor production. Moving forward, both parties will further promote its broad application in cell therapy.

Over the past two years, the two companies have established transparent and efficient collaboration mechanisms, validated by shared client successes. This strategic partnership will further consolidate their strengths to achieve multidimensional breakthroughs in process optimization, cost control, and product innovation. Together, they will provide seamless “bench-to-bedside” services, accelerating the global accessibility of cell and& gene therapies.

Breaking the Cost Barrier in Cell & Gene Therapy

Gene therapies currently face a $2M+/dose production cost barrier. By combining EurekaBio's manufacturing breakthroughs with VectorBuilder's process development and production expertise, this partnership aims to slash the cost of viral vector production, potentially making CGT treatments accessible to millions.

Leadership Vision

"This isn't just about better viral vectors – it's about redefining what's possible in cell and gene therapy," states Mr. Ma Marl, CEO of EurekaBio. "VectorBuilder's profound process development expertise and global network will amplify EuLV™'s impact across new therapeutic frontiers."

"Our synergy creates an innovation multiplier," emphasizes Dr. Jason Ye, VectorBuilder's VP of Technology. "Together, we're removing roadblocks that have hindered the field for decades."

About the Partners

EurekaBio – The cost-efficiency architect for CGT manufacturing, providing turnkey solutions from viral vectors (EuLV™) to automated cell processing (CellSep®).

VectorBuilder – A global gene delivery unicorn (est. 2023) whose platform has revolutionized custom vector access, supporting 50+ IND studies with FDA-compliant GMP materials.